Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
3.150
-0.230 (-6.80%)
Mar 31, 2025, 3:29 PM EDT - Market open
Eupraxia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Eupraxia Pharmaceuticals stock has a target of 9.00, which predicts an increase of 185.71% from the current stock price of 3.15.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Eupraxia Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +185.71% | Nov 14, 2024 |
Financial Forecast
Revenue This Year
n/a
from 60.29M
Revenue Next Year
n/a
EPS This Year
-0.69
from -0.76
EPS Next Year
n/a
from -0.69
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 47.7M | 60.5M | ||
| Avg | n/a | 46.3M | 31.9M | ||
| Low | n/a | 44.5M | 4.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 30.7% | ||
| Avg | - | - | -31.0% | ||
| Low | - | - | -89.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.71 | - | 0.42 | ||
| Avg | -0.69 | - | -0.15 | ||
| Low | -0.67 | - | -0.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.